[go: up one dir, main page]

SV2006002205A - Prodroga de benzoxazoles substituidos como agentes estrogenicos ref. wyth0108-504 (am101763) - Google Patents

Prodroga de benzoxazoles substituidos como agentes estrogenicos ref. wyth0108-504 (am101763)

Info

Publication number
SV2006002205A
SV2006002205A SV2005002205A SV2005002205A SV2006002205A SV 2006002205 A SV2006002205 A SV 2006002205A SV 2005002205 A SV2005002205 A SV 2005002205A SV 2005002205 A SV2005002205 A SV 2005002205A SV 2006002205 A SV2006002205 A SV 2006002205A
Authority
SV
El Salvador
Prior art keywords
wyth0108
benzoxazols
substituted
production
estrogenic agents
Prior art date
Application number
SV2005002205A
Other languages
English (en)
Inventor
Sayed Elmarakbi
Ping Cai
Appayu Chandrasekaran
Mark Edward Ruppen
Rasmy Talaat
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2006002205A publication Critical patent/SV2006002205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)

Abstract

PROPORCIONA MODULADORES DEL RECEPTOR DE ESTROGENOS DE LA FORMULA I, QUE TIENE LA SIGUIENTE ESTRUCTURA:, (VER FORMULA);EN DONDE Q1, Q2, R1, R2, E2A, R3, R3A Y X SON COMO SE DEFINE LA MEMORIA DESCRIPTIVA, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS
SV2005002205A 2004-08-26 2005-08-24 Prodroga de benzoxazoles substituidos como agentes estrogenicos ref. wyth0108-504 (am101763) SV2006002205A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60483504P 2004-08-26 2004-08-26

Publications (1)

Publication Number Publication Date
SV2006002205A true SV2006002205A (es) 2006-09-14

Family

ID=35750972

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002205A SV2006002205A (es) 2004-08-26 2005-08-24 Prodroga de benzoxazoles substituidos como agentes estrogenicos ref. wyth0108-504 (am101763)

Country Status (22)

Country Link
US (2) US20060046968A1 (es)
EP (1) EP1781628A2 (es)
JP (1) JP2008510827A (es)
KR (1) KR20070046148A (es)
CN (1) CN101044126A (es)
AR (1) AR050618A1 (es)
AU (1) AU2005280178A1 (es)
BR (1) BRPI0514628A (es)
CA (1) CA2576353A1 (es)
CL (1) CL2008000506A1 (es)
CR (1) CR8931A (es)
EC (1) ECSP077279A (es)
GT (1) GT200500228A (es)
IL (1) IL181236A0 (es)
MX (1) MX2007002251A (es)
NI (1) NI200700055A (es)
NO (1) NO20071159L (es)
PE (1) PE20060503A1 (es)
RU (1) RU2007105232A (es)
SV (1) SV2006002205A (es)
TW (1) TW200612925A (es)
WO (1) WO2006026316A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200800180A (en) * 2006-03-06 2008-01-01 Wyeth Corp Liquid and semi-solid pharmaceutical formulations and processes
WO2008057309A2 (en) * 2006-11-02 2008-05-15 Merck & Co., Inc. Estrogen receptor modulators
WO2008067425A1 (en) * 2006-11-30 2008-06-05 Wyeth Process for the synthesis of monosulfated derivatives of substituted benzoxazoles
CL2007003443A1 (es) * 2006-11-30 2008-07-11 Wyeth6 3 Compuestos derivados de benzoxazoles sustituidos; procedimiento de preparacion, utiles como agentes estrogenicos.
US20090010884A1 (en) * 2007-07-06 2009-01-08 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
US20110212923A1 (en) * 2008-02-08 2011-09-01 Pfizer Inc. Phosphate Derivatives of Substituted Benzoxazoles
WO2010036908A1 (en) * 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Use of benzoxazole compounds in the treatment of malaria
WO2010036905A1 (en) * 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Benzoxazole compounds and methods of use
WO2010083220A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzoxazole inhibitors of poly(adp-ribose)polymerase
KR20160007029A (ko) 2014-07-10 2016-01-20 삼성전기주식회사 압전 소자 및 이를 포함하는 압전 진동 모듈
EP3263109B1 (en) 2015-02-24 2020-06-17 National University Corporation Tottori University Drug for preventing and/or treating dementia
CN117045680B (zh) * 2023-10-12 2023-12-08 北京国卫生物科技有限公司 促进肝脏再生的干细胞制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU600138A1 (ru) * 1976-06-25 1978-03-30 Ленинградский Технологический Институт Имени Ленсовета Способ получени оксипроизводных 2-арилбензазолов
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
AU707798B2 (en) * 1995-06-23 1999-07-22 Advanced Life Sciences Inc. Biflavanoids and derivatives thereof as antiviral agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5919808A (en) * 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5948776A (en) * 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2000062765A2 (en) * 1999-04-16 2000-10-26 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
US7045539B2 (en) * 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
WO2002056969A2 (en) * 2001-01-18 2002-07-25 Acumen Manufacturing Limited 10k step exercise method and apparatus
EP1368037A2 (en) * 2001-03-16 2003-12-10 Wyeth Estrogen replacement therapy
US6559177B2 (en) * 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
WO2006026316A2 (en) 2006-03-09
CL2008000506A1 (es) 2008-06-13
RU2007105232A (ru) 2008-10-20
ECSP077279A (es) 2007-03-29
IL181236A0 (en) 2007-07-04
US20080255057A1 (en) 2008-10-16
AR050618A1 (es) 2006-11-08
NO20071159L (no) 2007-03-26
TW200612925A (en) 2006-05-01
CR8931A (es) 2007-08-28
CA2576353A1 (en) 2006-03-09
BRPI0514628A (pt) 2008-06-17
JP2008510827A (ja) 2008-04-10
KR20070046148A (ko) 2007-05-02
US20060046968A1 (en) 2006-03-02
GT200500228A (es) 2006-06-22
NI200700055A (es) 2008-02-27
MX2007002251A (es) 2007-04-20
EP1781628A2 (en) 2007-05-09
CN101044126A (zh) 2007-09-26
AU2005280178A1 (en) 2006-03-09
PE20060503A1 (es) 2006-07-20
WO2006026316A3 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
ECSP045133A (es) Benzoxazoles sustituidos y análogos como agentes estrogenicos
SV2006002205A (es) Prodroga de benzoxazoles substituidos como agentes estrogenicos ref. wyth0108-504 (am101763)
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
SV2002000356A (es) Nuevos derivados de piperazina ref. pc10770aixn/bb
NO20032253D0 (no) Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer
CO6241121A2 (es) Derivados de azapeptidps
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
CO6210720A2 (es) Derivados de azaadamantano y sus usos como ligandos de los receptores nicoticos de acetilcolina
NO20032161D0 (no) Tetrahydrobenzazepinderivater for anvendelse som modulatorer av dopamin D3-reseptorer (antipsykotiske midler)
DK1881967T3 (da) Substituerede benzo (D) isoaxol-3-yl-amin-forbindelser som analgetika
CO6311077A2 (es) Derivados de 1-(4-hidroxi-fenil)-1h-indol como ligandos novedosos de receptor de estrógeno
ATE470662T1 (de) Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor
MX2012005994A (es) Compuestos de 2-piridona.
CR8744A (es) Compuestos terapeuticos
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
CR11220A (es) Derivados de pirimidina 934
HN2009000968A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
CO6190619A2 (es) Derivados de 2- quinolinona y 2-quinoxalinona y su uso como agentes antibacterianos
ECSP088398A (es) Compuestos tricíclicos útiles como agonistas de receptores de oxitocina
UY31854A (es) Derivados sustituidos de 3-oxo-isoindolin-1- carboxamidas n-sustituidas y aplicaciones
AR074340A1 (es) Derivados de aminociclohexano y su uso en la fabricación de un medicamento para el tratamiento de una infección bacteriana.
MXPA05012279A (es) Derivados de bencil sulfonamida.
TW200643019A (en) Optically active tetrahydronaphthalene derivative